{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T22:32:42Z","timestamp":1774391562123,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12HD000850"],"award-info":[{"award-number":["K12HD000850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ccm.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:37:37Z","timestamp":1714451857000},"page":"625-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Care and Outcomes for Children with Cystic Fibrosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Bob Z.","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2024.03.006_bib1","unstructured":"Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. 2023."},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am J Dis Child"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcf.2020.08.008","article-title":"First description of cystic fibrosis","volume":"20","author":"Barben","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.107.1.1","article-title":"Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin cystic fibrosis neonatal screening study group","volume":"107","author":"Farrell","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.ccm.2024.03.006_bib6","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181s","author":"Farrell","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib7","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1542\/peds.2006-1993","article-title":"Guidelines for implementation of cystic fibrosis newborn screening programs: cystic Fibrosis Foundation workshop report","volume":"119","author":"Comeau","year":"2007","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.ccm.2024.03.006_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41436-020-0822-5","article-title":"CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"Deignan","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ppul.26253","article-title":"Refinement of newborn screening for cystic fibrosis with next generation sequencing","volume":"58","author":"Rock","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib11","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/AOG.0000000000001952","article-title":"Carrier screening for genetic conditions","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ccm.2024.03.006_bib12","author":"Hoskovec"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib13","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ppul.26296","article-title":"Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS\/CFSPID to CF reclassification","volume":"58","author":"Salinas","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ccm.2024.03.006_bib14","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jpeds.2016.09.066","article-title":"Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis","volume":"181s","author":"Ren","year":"2017","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ccm.2024.03.006_bib15","doi-asserted-by":"crossref","unstructured":"Green D.M., Lahiri T., Raraigh K.S., et al., Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS\/CFSPID. Pediatrics, 2024. Epub ahead of print.","DOI":"10.1542\/peds.2023-064657"},{"key":"10.1016\/j.ccm.2024.03.006_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3476(64)80290-0","article-title":"A\u00a0therapeutic regimen for patients with cystic fibrosis","volume":"65","author":"Matthews","year":"1964","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"Yen","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"6 Suppl","key":"10.1016\/j.ccm.2024.03.006_bib19","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis","volume":"155","author":"Borowitz","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib20","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1784","article-title":"Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis","volume":"137","author":"Lahiri","year":"2016","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jcf.2016.08.004","article-title":"Enteral tube feeding for individuals with cystic fibrosis: cystic Fibrosis Foundation evidence-informed guidelines","volume":"15","author":"Schwarzenberg","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib22","first-page":"Cd001198","article-title":"Enteral tube feeding for cystic fibrosis","volume":"7","author":"Shimmin","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcf.2021.12.014","article-title":"Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis","volume":"21","author":"Madde","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib25","first-page":"Cd001127","article-title":"Dornase alfa for cystic fibrosis","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib26","first-page":"Cd001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"6","author":"Wark","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00960-2021","article-title":"Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline","volume":"62","author":"Dwyer","year":"2023","journal-title":"Eur Respir J"},{"issue":"9290","key":"10.1016\/j.ccm.2024.03.006_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib29","first-page":"Cd008649","article-title":"Inhaled mannitol for cystic fibrosis","volume":"5","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib31","first-page":"CD001401","article-title":"Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis","volume":"4","author":"Warnock","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib32","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.ccm.2024.03.006_bib33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ppul.20914","article-title":"The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis","volume":"43","author":"Sawicki","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.ccm.2024.03.006_bib35","first-page":"CD009650","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"12","author":"Lo","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ccm.2024.03.006_bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib40","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"6","author":"Langton Hewer","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ccm.2024.03.006_bib41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ccm.2024.03.006_bib42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.ccm.2024.03.006_bib43","series-title":"Fluoroquinolones. Red book: 2021\u20132024 report of the committee on infectious diseases","author":"Committee on Infectious Diseases","year":"2021"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib44","first-page":"CD001021","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/clinids\/23.3.532","article-title":"Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation","volume":"23","author":"Saiman","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"S3","key":"10.1016\/j.ccm.2024.03.006_bib46","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: an update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib47","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.ccm.2024.03.006_bib48","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early pseudomonas infection in cystic fibrosis. the optimize randomized trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jcf.2021.08.024","article-title":"Exasperation with the lack of pulmonary exacerbation treatment standardization","volume":"20","author":"Hergenroeder","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A\u00a0randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2024.03.006_bib51","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A\u00a0pilot randomized trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.ccm.2024.03.006_bib52","first-page":"CD010966","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib54","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ppul.24454","article-title":"Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor","volume":"54","author":"Hamilton","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.ccm.2024.03.006_bib55","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib56","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2024.03.006_bib59","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cells11111769","article-title":"CFTR Modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib61","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib62","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A\u00a0case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib63","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib65","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","article-title":"Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor","volume":"14","author":"Siracusa","year":"2015","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.ccm.2024.03.006_bib67","doi-asserted-by":"crossref","DOI":"10.7326\/M16-0858","article-title":"Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study","author":"Stephenson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib68","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1164\/ajrccm.163.6.9912100","article-title":"The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States","volume":"163","author":"Schechter","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib69","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1164\/rccm.200306-779OC","article-title":"Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis","volume":"169","author":"Goss","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib70","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1378\/chest.12-2414","article-title":"Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis","volume":"144","author":"Farhat","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib71","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ppul.26335","article-title":"How many billions is enough? Prioritizing profits over patients with cystic fibrosis","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"18","key":"10.1016\/j.ccm.2024.03.006_bib72","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A\u00a0CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccm.2024.03.006_bib73","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2024.03.006_bib74","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib75","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.ccm.2024.03.006_bib77","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib78","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2024.03.006_bib79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2024.03.006_bib80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2024.03.006_bib81","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2024.03.006_bib82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ccm.2024.03.006_bib83","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A\u00a0Phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.ccm.2024.03.006_bib84","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2024.03.006_bib85","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2020.11.003","article-title":"A\u00a0phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation","volume":"20","author":"McKone","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.ccm.2024.03.006_bib86","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.ccm.2024.03.006_bib87","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ccm.2024.03.006_bib88","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523124000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523124000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T01:27:25Z","timestamp":1722043645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523124000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0272523124000364"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2024.03.006","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Care and Outcomes for Children with Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}